ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Articles tagged "High-risk"

  • 2021 American Transplant Congress

    Psmp is Discriminative for Chronic Active Antibody-Mediated Rejection and Predicts Graft Risk After Kidney Transplantation

    Y. Fu, P. Zhan

    Tianjin First Central Hospital, Tianjin, China

    *Purpose: Chronic active antibody-mediated rejection (c-aABMR) is an intermediate process in the development of chronic antibody-mediated rejection (c-ABMR), a key problem in the long-term failure…
  • 2021 American Transplant Congress

    Implementation of a High-risk Medication Report for Waitlisted Liver Transplant Candidates

    M. M. Eiting1, H. Yeh2, M. Cote1, S. Shao1, A. B. Scherrer2, L. Dageforde2, N. Elias2, C. Rogers Marks1

    1Pharmacy, Massachusetts General Hospital, Boston, MA, 2Massachusetts General Hospital, Boston, MA

    *Purpose: Use of high-risk medications (HRMs) at the time of liver transplant may lead to delays in surgery or peri-operative complications (bleeding, drug-drug interactions (DDI),…
  • 2020 American Transplant Congress

    Clinical and Laboratory Characteristics of Early and Late-Onset Cytomegalovirus Infection Following Universal Prophylaxis in Kidney Transplant Recipients

    M. M. Tavakol, B. Lee, S. Ashimine, H. Crossman, M. Park, Z. Laszik, J. Roberts

    University of California, San Francisco, San Francisco, CA

    *Purpose: Cytomegalovirus (CMV) is the most important viral infection in organ recipients and can cause life-threatening infections, compromising long-term graft function. Most transplant centers use…
  • 2020 American Transplant Congress

    Utility of Bimonthly Viral Monitoring for Late-Onset Cytomegalovirus Infections in Kidney Transplant Recipients

    I. Melgarejo1, D. Jorgensen2, S. Hariharan2, C. Puttarajappa2

    1Department of Medicine, Renal-Electrolyte Division, University of Pittsburgh, Pittsburgh, PA, 2Department of Surgery, Thomas E. Starzl Transplantation Institute, University of Pittsburgh, Pittsburgh, PA

    *Purpose: Kidney transplant recipients with high-risk cytomegalovirus (CMV) serostatus are at risk for late onset CMV after cessation of antiviral prophylaxis.1-2 Evidence for post-prophylactic viral…
  • 2020 American Transplant Congress

    An OPO’s Experience in Increasing Transplantation with the Hope Project

    R. P. Wood, M. Ferguson, K. Myer, R. Cruz, P. Gillentine

    CMO, LifeGift, Houston, TX

    *Purpose: The purpose of this report is to describe one OPO’s experience in participating in the Hope Project. This research project is designed to evaluate…
  • 2020 American Transplant Congress

    Ambient Air Pollution and Post-Transplant Mortality among US Kidney Transplant Recipients

    M. R. Jones1, Y. Feng2, N. Chu2, D. Segev2, M. McAdams-DeMarco1

    1Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, 2Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD

    *Purpose: Long-term exposure to fine particulate matter (PM2.5) has been associated with increased mortality in the general US population and has been shown to negatively…
  • 2020 American Transplant Congress

    Impact of the Baseline Anti-A/B IgG Titer on the Clinical Outcome in ABO-Incompatible Liver Transplantation

    J. Lee1, E. Kim1, S. Yang1, D. Kim2, M. Ju3, J. Lee1, M. Kim1, S. Kim1, D. Joo1

    1Department of Transplantation Surgery, Severance Hospital, Seoul, Korea, Republic of, 2Department of Surgery, Yonsei University Wonju College of Medicine, Wonju, Korea, Republic of, 3Department of Surgery, Gangam Severance Hospital, Seoul, Korea, Republic of

    *Purpose: The use of ABO incompatible (ABOi) living donors is an attractive solution for expanding the liver donor pool. We investigated the impact of the…
  • 2020 American Transplant Congress

    Donor-Derived Cell-Free DNA May Not Discriminate Rejection in Kidney Transplant Recipients with a Prior Allograft in Place

    A. Vo, M. Gillespie, S. C. Jordan, A. Peng, R. Najjar, S. Sethi, K. Lim, N. Ammerman, E. Huang

    Cedars-Sinai, Los Angeles, CA

    *Purpose: Donor-derived cell-free DNA (dd-cfDNA) is an injury biomarker discriminating rejection in kidney transplant (KTx) patients (pts). However, its performance when stratified by rejection risk…
  • 2020 American Transplant Congress

    Marginal Livers Have Excellent Outcomes in Pediatric Patients with Metabolic Liver Disease

    M. MacConmara, C. Feizpour, D. Desai, S. Hanish, P. Vagefi, A. Aqul, C. S. Hwang

    UT Southwestern, Dallas, TX

    *Purpose: Pediatric patients with metabolic diseases are listed so that livers are preferentially allocated to them, having the option of receiving a very high quality…
  • 2020 American Transplant Congress

    Evaluation of an Intervention to Reduce Underdosing of Valganciclovir for Primary Prophylaxis of Cytomegalovirus Infection in Donor Seropositive/Recipient Seronegative Kidney and Liver Transplant Recipients

    L. Al Bizri1, Z. S. Chaudhry2, A. Vahia2, J. Williams2, J. C. Lemos-Ramirez3, B. Summers4, A. Patel5, S. Nagai6, O. Abreu Lanfranco2, M. Ramesh2, R. Del Busto2, G. Alangaden2

    1Internal Medicine, Henry Ford Health System, Detroit, MI, 2Infectious Disease, Henry Ford Health System, Detroit, MI, 3Department of Transplant Infectious Disease, Memorial Regional Hospital, Hollywood, FL, 4Central Pharmacy, Henry Ford Health System, Detroit, MI, 5Nephrology, Henry Ford Health System, Detroit, MI, 6Surgery Transplant, Henry Ford Health System, Detroit, MI

    *Purpose: Valganciclovir (VCV) prophylaxis is used to prevent primary cytomegalovirus (CMV) infection in CMV donor seropositive/recipient seronegative (D+/R-) solid organ transplant recipients (SOT). We examined…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 15
  • Next Page »

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences